Versius extends DEPLOY's surgical cluster along a second axis: where the Wave 1 triangle (da Vinci, Hugo, Ottava) varies by FDA-clearance posture in general laparoscopy, Versius adds clinical-domain and geography variance, the international-soft-tissue archetype with a modular multi-arm architecture distinct from da Vinci's monolithic design.
✔
Its commercial footprint is genuinely international (CE-marked across Europe, Latin America, AMEA, and Australia), and it is now US-FDA-cleared for cholecystectomy (De Novo October 2024; Versius Plus 510(k) December 2025).
Price
No reviewed price is on record. We do not treat unverified analyst estimates as pricing data. There is no consumer price. Versius is enterprise B2B surgical equipment sold to hospitals on per-system contracts, so DEPLOY records zero price points rather than a consumer figure.
Availability
Internal use only
Versius is sold to hospitals, not consumers. From UK-based CMR Surgical, it is CE-marked and commercial across Europe, Latin America, AMEA, and Australia, and US-FDA-cleared for cholecystectomy (De Novo, October 2024; Versius Plus 510(k), December 2025).
Real-world status
CMR Surgical's Versius (and Versius Plus) is a modular, multi-arm, soft-tissue minimal-access surgical robot and the international-soft-tissue archetype of DEPLOY's surgical cluster. Its modular multi-arm architecture is a deliberate contrast to the monolithic design of Intuitive's da Vinci: it is teleoperated and software-driven, capturing telematic, video, and outcome data. On regulatory status: Versius is US-FDA-cleared for cholecystectomy via a De Novo authorization in October 2024, with Versius Plus cleared via 510(k) on December 18, 2025, and a gynecology 510(k) submitted April 29, 2026 (pending). It is not broadly 'US-pending'; only the gynecology indication is.
A correction to common framing: Versius is not broadly 'US-pending'. It is US-cleared for cholecystectomy; only the gynecology indication (510(k) submitted April 2026) is pending. Read the cleared scope by indication, not as a blanket status.
⊘
There is no consumer price. Versius is sold to hospitals on per-system contracts, so DEPLOY records zero price points.
No⊘absence. It is enterprise B2B surgical equipment sold to hospitals on per-system contracts; there is no consumer price.
Is the Versius FDA-cleared in the US?
Yes, for cholecystectomy🟢verified: a De Novo authorization (October 2024) plus a Versius Plus 510(k) (December 2025). A gynecology 510(k) was submitted April 2026 and is pending.
How is Versius different from da Vinci?
Versius is modular multi-arm🟢verified, a deliberate contrast to da Vinci's monolithic design; both are teleoperated soft-tissue systems.
Where is Versius used?
CE-marked and commercial across Europe, Latin America, AMEA, and Australia🟢verified, plus US clearance for cholecystectomy.
How does Versius compare to the rest of the cluster?
It is the international-soft-tissue archetype🟢verified; the Wave 1 triangle (da Vinci, Hugo, Ottava) varies by FDA posture, while Versius adds geography and a modular architecture.
Pricing and availability are tagged verified or claimed against primary sources. Manufacturer targets are reported as targets, not prices you can pay today.